Rabzak 20 Akriti medicine for gastroesophageal reflux treatment, esophagus (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Rabeprazole

Ingredient

Composition information	Content
Rabeprazole	20mg

Uses

Indications

Rabzak 20 drugs are indicated in the following cases:

Gastroesophageal reflux disease. H2 h2 receptor antagonist, but prevent stomach acid secretion by inhibiting H+, K+ ATPASE at the surface of the secretion of the border of the stomach.

Because this enzyme acts as an acid pump inside the border cell, Rabeprazole is considered a stomach proton pump inhibitor. Rabeprazole inhibits the final step of gastric acid secretion. In the border cells of the stomach, Rabeprazole is protonized, accumulated and transformed into a form of activity sulfenamid.

pharmacokinetics

Rabeprazole's peak in plasma concentration is about 3.5 hours after drinking.

Oral bioavailability is about 52%, because there is the first metabolism of the liver, so the difference between the single dose and the dose is repeated. Rabeprazole binds 97% to plasma protein.

The drug is strongly metabolized through the liver by the Cytochrom P450 ISOENZYM CYP2C19 and CYP3A4 systems into Thiioether, the acid of Carboxylic, sulfon and Desmethylthioether.

The metabolites are excreted mainly in urine (about 90%) and the rest through feces.

Semi -selling time in plasma is about 1 hour, increasing to 2-3 times in the event of liver failure, 1.6 times in those who are slowly metabolized through CYP2C19 and an increase of 30% in the elderly.

Before taking Rabzak 20 Akriti medicine for gastroesophageal reflux treatment, esophagus (3 blisters x 10 tablets)

How to use

Rabzak 20 medicine is used by oral.

The drug is usually taken in the morning.

Dosage

Gastroesophageal reflux disease - Severe esophagus

The usual dose of Rabeprazole sodium is 20 mg/ day/ day for 4-8 weeks. After that, continue treatment for 10 mg or 20 mg per day depending on the response of the patient.

Digestive ulcerative disease

20 mg/ day for 4 - 8 weeks for duodenal ulcer and 6-12 weeks for stomach ulcers.

Zollinger syndrome - Ellison

Starting dose 60 mg/day/day, adjust the dose according to the patient's response. The dose may increase to 120 mg/ day; When the daily dose is higher than 100 mg should be divided into 2 times.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

Handling

There is no specific anti -toxic drug. Because rabeprazol is very strong with protein, it cannot be eliminated by fertilizer method. In case of overdose, it is necessary to treat symptoms and support treatment.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using Rabzak 20, you may experience unwanted effects (ADR).

The most unwanted effect with Rabeprazole and other proton pump inhibitors are headaches, diarrhea and skin.

Other undesirable effects include itching, dizziness, drowsiness, fatigue, constipation, nausea and vomiting, flatulence, abdominal pain, joint pain and muscle pain, urticaria and dry mouth.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Rabzak 20 drugs contraindicated in the following cases:

Hypersensitivity to Rabeprazol, the derivatives of benzimidazol (e.g. ezomeprazol, lanzoprazol, omeprazol, pantoprazol) and any ingredients in the drug.

pregnant women.

Precautions when using

responding to symptoms for Rabeprazol therapy does not rule out the existing stomach or esophagus tumors; Therefore, it is necessary to eliminate the possibility of a malignant tumor before treatment with Rabeprazol. Treatment lasts more than a year with rabeprazol that needs periodic monitoring.

Be cautious when using rabeprazol because of the risk of hypersensitivity reactions to other proton pump inhibitors or benzimidazol derivatives when used instead.

Do not use rabeprazol for children because they have no experience to use. There have been post -commercial reports on hematuria disorders such as thrombocytopenia and neutropenia. In the majority of cases, these disorders are not serious and will stop using Rabeprazol.

In clinical trials and after use, there are abnormal liver enzyme reports. If there is no other cause, these enzyme disorders are not serious and will stop using rabeprazol. A controlled study on patients with liver failure from medium to severe comparison with good people and gender has not seen serious problems related to the safety of the drug. However, because there is no clinical data on the use of rabeprazol to treat severe liver failure, it is necessary to be very careful when indicating the first sodium rabeprazole for the patients.

Treatment with proton pump inhibitors, including rabeprazol, may increase the risk of gastrointestinal tract infections with Salmonella, Campylobacter and Clostridium difficile.

Do not be indicated to combine sodium rabeprazol with Atazanavir. Do not use rabeprazol for patients with galactose intolerance due to genetics, deficiency of lapp lactase enzymes or impaired glucose, galactose absorption.

The ability to drive and operate machinery

capable of Rabeprazole affects the ability to drive or control machinery. Due to drowsiness affects alertness, recommendations when using Rabeprazol must not drive or control machines.

Pregnancy

There is no complete and strict research on pregnant women. Because animal reproductive studies do not always predict the response in humans, this drug is contraindicated for pregnant women.

Breastfeeding period

It is unclear whether Rabeprazole is excreted through breast milk or not; Stop breastfeeding or stopping medication because the drug is likely to be harmful to breastfed babies.

Drug interaction

with ketoconazol or iTraconazole

may reduce the absorption of ketoconazole or itraconazole. Therefore, if used to monitor the adjustment of ketoconazole or iTraconazole.

Avoid simultaneously rabeprazol with

erlotinib, nelfinavir, delavirdin, posaconazole.

Sometimes, Atazanavir 300 mg/ritonavir 100 mg along with sodium Rabeprazol is only 40 mg/day or Atazanavir 400 mg with a single dose of lanzoprazols 60 mg/day on healthy volunteers shows a sharp reduction in acanavir levels. Atazanavir absorption depends on pH. Although it has not been studied, it is thought that the phenomenon also occurs with other proton pump inhibitors.

Rabeprazol may reduce the concentration/effect of Atanazavir, Clorpidogrel, Dabigatran, Ethilat, Dasatinib, Erlotinib, Indinavir, Iron Salt, Itraconazol, Ketoconazol, Mesalamin, Mycophenolat, Nelfinavir.

Rabeprazol may increase the concentration/effect of the drugs that are CYP2C19, CYP2C8 (high levels of risk), methotrexate, Saquinavir, Voriconazol.

Storage

Store in closed packaging, dry place, avoid moisture. The temperature does not exceed 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.